HK Stock Market Move | CHINARES PHARMA (03320) rises nearly 5% again, with revenue and net profit exceeding expectations last year. Management has proposed several outlooks.

CHINARES PHARMA (03320) rose nearly 5% again, with a cumulative increase of over 25% after the results announcement. As of the time of writing, it was up 4.88% to HK$5.59, with a turnover of HK$2.48 billion. On the news front, CHINARES PHARMA reported annual results, with group revenue reaching RMB 269.574 billion, a year-on-year increase of 4.62%; shareholders' net profit was RMB 4.045 billion, a year-on-year increase of 20.73%; earnings per share were 0.64 yuan; and a final dividend of 0.122 yuan was proposed, representing an increase of about 1.35 times compared to the same period last year. Lyon said that CHINARES PHARMA's annual revenue and profit exceeded market expectations. CMSC International pointed out that the company's management did not provide specific revenue or profit guidance for the 2026 fiscal year, but qualitative signals were conveyed during the performance meeting: in the 2026 fiscal year reporting period, efforts will be made to achieve high single-digit revenue growth and good profit growth; the dividend payout ratio will be maintained at 30%, and if there are no major mergers and acquisitions, consideration will be given to increasing the dividend ratio, with reference to A-share listed companies having a dividend payout ratio of over 30%; the impairment pressure will be greatly reduced in 2025; the strategy of acquiring blood products will continue, choosing the right time, place, and price to complete industry consolidation, and entering the blood product market with strong strategic significance.